Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242339 (dyslipidemia)
 13,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Metabolic syndrome represents a collection of cardiovascular risk factors, including overweight, hypertension, dyslipidemia and impaired glucose metabolism, with insulin resistance. In recent years, the potential relationship between metabolic syndrome and male factor infertility has been studied. As endothelial dysfunction is the hallmark of metabolic syndrome, the aim of this work was to assess serum levels of YKL-40 as a marker of endothelial dysfunction in male patients with idiopathic infertility. The study revealed that YKL-40 levels were elevated in patients than controls denoting that endothelial dysfunction might play a role in the pathogenesis of idiopathic infertility and that YKL-40 as a marker of endothelial dysfunction could be a useful marker of idiopathic infertility.
 ...
PMID:Endothelial dysfunction marker YKL-40 is elevated in male patients with idiopathic infertility. 2939 59

Dyslipidaemia is associated with numerous health problems that include the combination of insulin resistance, hypertension and obesity, ie, metabolic syndrome. Although the use of statins to decrease serum low density lipoprotein cholesterol (LDL-C) has been an effective therapeutic in treating atherosclerosis, the persistence of high atherosclerotic risk, ie, residual risk, is notable and is not simply explained as a phenomenon of dyslipidaemia. As such, it is imperative that we identify new biomarkers to monitor treatment and more accurately predict future cardiovascular events. This athero-protective strategy includes the assessment of novel inflammatory biomarkers such as YKL-40. Recent evidence has implicated YKL-40 in patients with inflammatory diseases and cardio-metabolic disorders, making it potentially useful to evaluate disease severity, prognosis and survival. In this review, we summarize role of YKL-40 in the pathogenesis of cardio-metabolic disorders and explore its use as a novel biomarker for monitoring athero-protective therapy.
 ...
PMID:YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. 3300 71